Brief: Daewoong Pharmaceutical Unveils Phase 3 Clinical Data Of Fexuprazan, A Novel Potassium-Competitive Acid Blocker
08/05/2020 14:12
May 8 (Reuters) - Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL UNVEILS PHASE 3 CLINICAL DATA OF
FEXUPRAZAN, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER
* DAEWOONG PHARMA - FEXUPRAZAN SHOWED 99% OF MUCOSAL HEALING
RATE
AT WEEK 8 AND WAS WELL TOLERATED IN PATIENTS
* DAEWOONG PHARMA - FEXUPRAZAN ALSO SHOWED IMPROVED SYMPTOM
RELIEF
* DAEWOONG PHARMA - ATYPICAL SYMPTOM SUCH AS COUGH WAS ALSO
IMPROVED WITH TREATMENT OF FEXUPRAZAN
* DAEWOONG PHARMA - IN PATIENTS WITH MODERATE TO SEVERE
SYMPTOMS,
FEXUPRAZAN EXHIBITED SIGNIFICANTLY FASTER, BETTER HEARTBURN
RELIEF VERSUS ESOMEPRAZOLE
Source text for Eikon: ID:nCNW2xQGXa
Further company coverage: 069620.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier